Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

被引：1

作者：

Ravi, Gayathri ^{[1
]}

Giri, Smith ^{[2
]}

Bal, Susan ^{[3
]}

Godby, Kelly N. ^{[4
]}

Reddy, Vishnu V. B. ^{[5
]}

Salzman, Donna ^{[6
]}

Alkharabsheh, Omar ^{[7
]}

McDaniel, Scott A. ^{[8
]}

Sentell, Melissa ^{[6
]}

Costa, Luciano J. ^{[9
]}

机构：

[1] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Inst Canc Outcomes & Survivorship, Birmingham, AL USA

[3] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[4] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham Hosp, Birmingham, AL USA

[5] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] Univ S Alabama, Mitchell Canc Inst, Mobile, AL USA

[8] Alabama Oncol Hematol Associates, Montgomery, AL USA

[9] Univ Alabama, Birmingham Hosp, Vestavia, AL USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-170099

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：8048 / 8049

页数：2

共 50 条

[41] Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis
Ficek, Joseph
Kalaitzaki, Eleftheria
Yuan, Shuai Sammy
Tosolini, Alessandra
Du, Ling
Kremer, Brandon E.
Davy, Katherine
Zhou, Helen
Chen, Tai-Tsang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (05): : E213 - E221
[42] Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.
Oliva, Stefania
Bruinink, Davine Hofste op
RIhova, Lucie
Spada, Stefano
van der Holt, Bronno
Troia, Rossella
Gambella, Manuela
Pantani, Lucia
Grammatico, Sara
Gilestro, Milena
Offidani, Massimo
Ribolla, Rossella
Galli, Monica
Hajek, Roman
Palumbo, Antonio
Cava, Michele
Omede, Paola
van der, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[43] Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study
Torka, Pallawi
Reddy, Nishitha
Groman, Adrienne
Kader, Angela
Nichols, Jenna
Hutson, Alan
Mavis, Cory
Tario, Joseph Dennis
Wallace, Paul K.
Block, AnneMarie W.
Sait, Sheila N. J.
Baysal, Bora E.
Neppalli, Vishala T.
Sundaram, Suchitra
Hernandez-Ilizaliturri, Francisco J.
BLOOD, 2019, 134
[44] Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.
Shah, Nina
Patel, Sharmila
Pei, Huiling
Qi, Ming
Krevvata, Maria
Lin, Thomas S.
Khare, Vipin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[45] Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities
Korde, Neha
Mailankody, Sham
Roschewski, Mark
Faham, Malek
Kotwaliwale, Chitra
Moorhead, Martin
Kwok, Mary L.
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Costello, Rene
Zhang, Yong
Zingone, Adriana
Burton, Debbie
Mulquin, Marcia
Carpenter, Ashley
Zuchlinski, Diamond
Lamping, Elizabeth
Carter, George
Morrison, Candis
Kurdziel, Karen
Lindenberg, Maria
Kurlander, Roger
Maric, Irina
Calvo, Katherine R.
Braylan, Raul C.
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Steinberg, Seth M.
Figg, William D.
Choyke, Peter
Landgren, Ola
BLOOD, 2014, 124 (21)
[46] Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial
Oliva, Stefania
Genuardi, Elisa
Petrucci, Maria Teresa
D'Agostino, Mattia
Auclair, Daniel
Spadano, Antonio
Jacob, Allison P.
Cea, Michele
De Rosa, Luca
Gozzetti, Alessandro
Ruggeri, Marina
Capra, Andrea
Gilestro, Milena
Pescosta, Norbert
Palmas, Angelo D.
Siniscalchi, Agostina
Kirsch, Ilan R.
Corradini, Paolo
Musto, Pellegrino
Boccadoro, Mario
Zamagni, Elena
Gay, Francesca
BLOOD, 2020, 136
[47] A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Silvennoinen, Raija Helena
Waage, Anders
Peceliunas, Valdas
Schjesvold, Fredrik
Mdphd
Anttila, Pekka
Saily, Marjaana
Putkonen, Mervi
Carlson, Kristina
Haukaas, Einar
Sankelo, Marja
Partanen, Anu
Szatkowski, Damian L.
Hansson, Markus
Marttila, Anu
Ahlberg, Lucia
Axelsson, Per
Lauri, Birgitta
Mikkola, Maija Helena
Karlsson, Conny
Abelsson, Johanna
Ahlstrand, Erik
Sikio, Anu
Klimkowska, Monika
Matuzeviciene, Reda
Fenstad, Mona Hoysaeter
Ilveskero, Sorella
Nahi, Hareth
BLOOD, 2020, 136
[48] The utility of minimal residual disease (MRD) assessment in post-first relapse re-induction: results from the BSBMT/UKMF Myeloma X (intensive) Trial
Owen, R. G.
DeTute, D. M.
Ashcroft, A. J.
Cairns, D. A.
Fletcher, M.
Williams, C.
Cavenagh, J. D.
Snowden, J. A.
Rawstron, A. C.
Parrish, C.
Morris, T. C.
Brown, J. M. B.
Cook, G.
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 65 - 66
[49] Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Costa, Luciano J.
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai R.
Schmidt, Timothy M.
Godby, Kelly N.
Silbermann, Rebecca
Dhakal, Binod
Bal, Susan
Giri, Smith
D'Souza, Anita
Hall, Aric C.
Hardwick, Pamela
Omel, James
Cornell, Robert F.
Hari, Parameswaran
Callander, Natalie S.
LANCET HAEMATOLOGY, 2023, 10 (11): : e890 - e901
[50] Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial
Cloos, Jacqueline J.
Montesinos, Pau
Fiedler, Walter
Mueller, Rouven
Krauter, Juergen
Sica, Simona
Westermann, Joerg
Heidinga, Maaike E.
Ngai, Lok Lam
Oussoren-Brockhoff, Yvonne J. M.
Doehner, Hartmut
Levis, Mark
Ossenkoppele, Gert J.
Stone, Richard M.
Koenen, Giedre
Bengoudifa, Bourras-Rezki
Cheng, Yuan
Medts, Thierry
Heidinger, Valerie
Sachs, Carolin
Sierra, Jorge
BLOOD, 2021, 138

← 1 2 3 4 5 →